Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancer
Phase 2
- Conditions
- Advanced or recurrent esophageal cancer
- Registration Number
- JPRN-UMIN000005877
- Lead Sponsor
- Toho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
(1) patient who has drug allergy as past history 1. Known hypersensitivity to DOC, NDP and Polysorbate-80 2. patient who has active infectious disease 3. patient who has active double cancer 4. patient who has severe complication (interstitial pneumonitis, DM etc.) 5.concomitant treatment with steroids 6.EDEMA 7. patient who want to be pregnant and /or pregnant woman 8. patient who was judged to be unsuitable for this clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method overall survival, one year survival rate, progression free survival, objective response rate, adverse events